Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit

Journal of Molecular and Cellular Cardiology

Volumn 30, Issue 6, 1998, Pages 1115-1128

  Sato, Satoshi ^a   Talukder, M A Hassan ^a   Sugawara, Hiromi ^a   Sawada, Hironobu ^a   Endoh, Masao ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Aequorin; Ca2+ sensitizer; Carbachol; Indo 1; Levosimendan; Phosphodiesterase inhibitor; Rabbit, papillary muscle; Single ventricular cardiomyocyte

Indexed keywords

AEQUORIN; CALCIUM ION; CARBACHOL; INDO 1; LEVOSIMENDAN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM CURRENT; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART PAPILLARY MUSCLE; HEART RIGHT VENTRICLE; INOTROPISM; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0032104314     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.1998.0677     Document Type: Article

References (45)

1. BAIM DS, MCDOWELL AV, CHERNILES J, MONRAD ES, PARKER JA, EDELSON J, BRAUNWALD E, GROSSMAN W, 1983. Evaluation of a new bipyridine inotropic agent -milrinone - in patients with severe congestive heart failure. N Engl J Med 309: 748-756.
2. 2+ as an inotropic mechanism. Circulation 73 (Suppl. III): III-85-III-98.
3. BLINKS JR, MATTINGLY PH, JEWELL BR, VAN LEEUWEN M, HARRER GC, ALLEN DG, 1978. Practical aspects of the use of acquorin as a calcium indicator: assay, preparation, microinjection, and interpretation of signals. Methods Enzymol 57: 292-328.
4. BÖHM M, MORANO I, PIESKE B, RÜEGG JC, WANKERL M, ZIMMERMANN R, ERDMANN E, 1991. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ Res 68: 689-701.
5. BOKNIK P, NEUMANN J, KASPAREIT G, SCHMITZ W, SCHOLZ H, VAHLENSIECK U, ZIMMERMANN N, 1997. Mechanisms of the contractile effects of levosimendan in the mammalian heart. J Pharmacol Exp Ther 280: 277-283.
6. BRÜCKNER R, SCHMITZ W, SCHOLZ H, SCHUMACHER A, ERDMANN E, KRAWIETZ W, WERDAN K, 1980. Negative inotropic effect of vanadate in ventricular myocardium in the presence of 3-isobutyl-1-methylxanthine or isoprenaline. Naunyn-Schmiedeberg's Arch Pharmacol 315: 147-153.
7. DIBIANCO R, SHABETAI R, KOSTUK W, MORAN J, SCHLANT RC, WRIGHT R, MILRINONE MULTICENTER TRIAL GROUP, 1989. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 320: 677-683.
8. f) by cAMP in the rabbit sino-atrial node. J Physiol 474: 473-482.
9. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 77: 107-113.
10. ENDOH M, 1990. Characteristics of regulation of intracellular calcium mobilization and sensitivity by β-adrenoceptor and muscarinic agonists, and a novel inotropic agent, MCI-154, in canine ventricular myocardium. In: Yamada K, Shibata S, Katz AM and Fabiato F (eds). Recent Advances in Ca Channels and Ca-antagonists. New York: Pergamon Press, 51-59.
11. ENDOH M, 1995. The effects of various drugs on the myocardial inotropic response. Gen Pharmacol 262: 1-31.
12. 2+ mediated through α- and β-adrenoceptors. Circ Res 62: 247-265.
13. ENDOH M, MOTOMURA S, 1979. Differentiation by cholinergic stimulation of positive inotropic actions mediated via α- and β-adrenoceptors in the rabbit heart. Life Sci 25: 759-768.
14. FARAH AE, ALOUSI AA, SCHWARZ RP JR, 1984. Positive inotropic agents. Ann Rev Pharmacol Toxicol 24: 275-328.
15. 2+ sensitivity in rabbit single ventricular cardiomyocytes loaded with indo-1/AM: comparison with the effects of phenylephrine and angiotensin II. J Cardiac Failure 2: S45-S57.
16. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260: 3440-3450.
17. HAIKALA H, LINDÉN IB, 1995. Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol 26 (Suppl. 1): S10-S19.
18. HAIKALA H, KAIVOLA J, NISSINEN E, WALL P, LEVIJOKI J, LINDÉN IB, 1995a. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 27: 1859-1866.
19. HAIKALA H, LEVIJOKI J, LINDÉN IB, 1995b. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J Mol Cell Cardiol 27: 2155-2165.
20. HAIKALA H, NISSINEN E, ETEMADZADEH E, LEVIJOKI J, LINDÉN IB, 1995c. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 25: 794-801.
21. HAIKALA H, KAHEINEN P, LEVIJOKI J, LINDÉN IB, 1997. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res 34: 536-546.
22. HAJJAR RJ, GWATHMEY JK, 1991. Calcium-sensitizing inotropic agents in the treatment of heart failure: a critical view. Cardiovasc Drugs Ther 5: 961-966.
23. 2+ sensitizers impair cardiac relaxation in failing human myocardium. J Pharmacol Exp Ther 280: 247-254.
24. HASENFUSS G, PIESKE B, KRETSCHMANN B, HOLUBARSCH C, ALPERT NR, JUST H, 1995. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. J Cardiovasc Pharmacol 26 (Suppl. 1): S45-S51.
25. KAWABATA Y, ENDOH M, 1993. Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ Res 72: 597-606.
26. KURIHARA S, KONISHI M, 1987. Effects of β-adrenoceptor stimulation on intracellular Ca transients and tension in rat ventricular muscle. Pflügers Arch 409: 427-437.
27. LUES I, BEIER N, JONAS R, KLOCKOW M, HAEUSLER G, 1993. The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers. J Cardiovasc Pharmacol 21: 883-892.
28. MÜLLER-BECKMANN B, FREUND P, HONERJÄGER P, KLING L, RÜEGG JC, 1988. In vitro investigations on a new positive inotropic and vasodilating agent (BM 14.478) that increases myocardial cyclic AMP content and myofibrillar calcium sensitivity. J Cardiovasc Pharmacol 11: 8-16.
29. NEUMANN J, ESCHENHAGEN T, GRUPP IL, HAVERICH A, HERZIG JW, HIRT S, KALMÁR P, SCHMITZ W, SCHOLZ H, STEIN B, WENZLAFF H, ZIMMERMANN N, 1996. Positive inotropic effects of the calcium sensitizer CGP 48506 in failing human myocardium. J Pharmacol Exp Ther 277: 1579-1585.
30. 2+ transients and contractile properties by β-adrenoceptor stimulation in ferret ventricular muscles. J Physiol 423: 221-240.
31. PACKER M, CARVER JR, RODEHEFFER RJ, IVANHOE RJ, DIBIANCO R, ZELDIS SM, HENDRIX GH, BOMMER WJ, ELKAYAM U, KUKIN ML, MALLIS GI, SOLLANO JA, SHANNON J, TANDON PK, DEMETS DL, FOR THE PROMISE STUDY RESEARCH GROUP, 1991. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325: 1468-1475.
32. PAGEL PS, HAIKALA H, PENTIKÄINEN PJ, TOIVONEN ML, NIEMINEN MS, LEHTONEN L, PAPP JG, WARLTIER DC, 1996. Pharmacology of levosimendan: a new myofilament calcium sensitizer. Cardiovascular Drug Rev 14: 286-316.
33. 2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem 269: 28584-28590.
34. RAASMAJA A, TALO A, NISSINEN E, LINDÉN IB, POHTO P, 1991. Biochemical mechanisms of novel cardiotonic agent OR-1259 (Abstract). J Mol Cell Cardiol 23 (Suppl. V): S129.
35. REMME WJ, KRUIJSSEN DACM, VAN HOOGENHUYZE DCA, KRAUSS XH, BARTELS GL, STORM CJ, DE LEEUW PW, 1994. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure. J Cardiovasc Pharmacol 24: 730-739.
36. SCHÜMANN HJ, ENDOH M, WAGNER J, 1974. Positive inotropic effects of phenylephrine in the isolated rabbit papillary muscle mediated both by α-and β-adrenoceptors. Naunyn-Schmiedeberg's Arch Pharmacol 284: 133-148.
37. SOLARO RJ, GAMBASSI G, WARSHAW DM, KELLER MR, SPURGEON HA, BEIER N, LAKATTA EG, 1993. Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments. Circ Res 73: 981-990.
38. SPURGEON HA, DUBELL WH, STERN MD, SOLLOTT SJ, ZIMAN BD, SILVERMAN HS, CAPOGROSSI MC, TALO A, LAKATTA EG, 1992. Cytosolic calcium and myofilaments in single rat cardiac myocytes achieve a dynamic equilibrium during twitch relaxation. J Physiol 447: 83-102.
39. + exchange to the positive inotropic effect of phenylephrine, endothelin-3 and angiotensin II in rabbit ventricular myocardium. Naunyn-Schmiedeberg's Arch Pharmacol 355: 87-96.
40. TODAKA K, WANG J, YI GH, STENNETT R, KNECHT M, PACKER M, BURKHOFF D, 1996. Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther 279: 120-127.
41. VÉGH Á, PAPP JG, UDVARY É, KASZALA K, 1995. Hemodynamic effects of calcium-sensitizing agents. J Cardiovasc Pharmacol 26 (Suppl. 1): S20-S31.
42. 2+ sensitizer Org-30029 reverses acidosis- and BDM-induced contractile depression in canine myocardium. Am J Physiol 271: H1829-H1839.
43. 2+ in isolated ferret cardiac muscle. Circ Res 73: 61-70.
44. + channel in rat ventricular cells. J Pharmacol Exp Ther 283: 375-383.
45. 2+] related to rate of force development in twitch contraction of heart. Am J Physiol 252: H760-H770.